VRDN - Viridian Therapeutics, Inc.\DE

QQQ $ 613.65 $ -8.14 (-1.31 %)

DIA $ 469.25 $ -2.78 (-0.59 %)

SPY $ 671.36 $ -5.11 (-0.76 %)

TLT $ 89.71 $ 0.15 (0.17 %)

GLD $ 366.56 $ -0.60 (-0.16 %)

Previous Close

$ 24.42

Open

$ 25.15

Bid

$ 28.17 x 220

Ask

$ 28.22 x 210

Day's Range

$ 25.07 - $ 28.54

52 Week Range

$ 9.90 - $ 27.20

Volume

2,619,744

Average Volume

Market Cap

2.33B

Beta (5Y Monthly)

$ 0.79

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-05-2025	09-30-2025	10-Q
2	08-06-2025	06-30-2025	10-Q
3	05-06-2025	03-31-2025	10-Q
4	03-03-2025	01-01-1970	10-K
5	11-12-2024	09-30-2024	10-Q
6	08-08-2024	06-30-2024	10-Q
7	05-08-2024	03-31-2024	10-Q
8	02-27-2024	12-31-2023	10-K
9	11-13-2023	09-30-2023	10-Q
10	08-08-2023	06-30-2023	10-Q
11	05-10-2023	03-31-2023	10-Q
12	03-09-2023	12-31-2022	10-K
13	11-14-2022	09-30-2022	10-Q
14	08-15-2022	06-30-2022	10-Q
15	05-13-2022	03-31-2022	10-Q
16	03-11-2022	12-31-2021	10-K
17	11-05-2021	09-30-2021	10-Q
18	08-12-2021	06-30-2021	10-Q
19	05-07-2021	03-31-2021	10-Q
20	03-26-2021	12-31-2020	10-K
21	11-12-2020	09-30-2020	10-Q
22	08-05-2020	06-30-2020	10-Q
23	05-08-2020	03-31-2020	10-Q
24	03-13-2020	12-31-2019	10-K
25	11-08-2019	09-30-2019	10-Q
26	08-08-2019	06-30-2019	10-Q
27	05-09-2019	03-31-2019	10-Q
28	03-14-2019	12-31-2018	10-K
29	11-07-2018	09-30-2018	10-Q
30	08-08-2018	06-30-2018	10-Q
31	05-09-2018	03-31-2018	10-Q
32	03-15-2018	12-31-2017	10-K
33	11-09-2017	09-30-2017	10-Q
34	08-11-2017	06-30-2017	10-Q
35	05-11-2017	03-31-2017	10-Q
36	03-24-2017	12-31-2016	10-K
37	10-26-2016	09-30-2016	10-Q
38	08-15-2016	06-30-2016	10-Q
39	05-16-2016	03-31-2016	10-Q
40	03-21-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

RBC Capital Maintains Outperform on Viridi...
11/06/2025 16:30:44

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target ...

Viridian Therapeutics Q3 EPS $(0.34) Beats...
11/05/2025 12:25:35

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of...

BTIG Reiterates Buy on Viridian Therapeuti...
11/04/2025 10:20:09

BTIG analyst Julian Harrison reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $61 price target.

Viridian Therapeutics Submits BLA To FDA F...
11/03/2025 12:11:10

- BLA for veligrotug successfully submitted to the U.S. Food and Drug Administration (FDA) in late October following recent con...

Reported Earlier, Viridian Therapeutics Pr...
10/22/2025 07:26:19

Viridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock, together wit...

Viridian Therapeutics Launches An Underwri...
10/21/2025 20:03:23

Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing poten...

Expert Outlook: Viridian Therapeutics Thro...
10/21/2025 20:00:39

DRI Healthcare Trust Acquires Royalty Inte...
10/20/2025 11:34:52

10 Health Care Stocks With Whale Alerts In...
09/29/2025 17:35:29

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

these-analysts-revise-their-forecasts-on-viridian-therapeutics-following-q2-results

These Analysts Revise Their Forecasts On V...
08/07/2025 18:37:46

Goldman Sachs Maintains Buy on Viridian Th...
08/07/2025 17:53:04

Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from ...

RBC Capital Maintains Outperform on Viridi...
08/07/2025 15:34:16

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target ...

Wells Fargo Maintains Equal-Weight on Viri...
08/07/2025 14:36:11

Wells Fargo analyst Derek Archila maintains Viridian Therapeutics (NASDAQ:VRDN) with a Equal-Weight and lowers the price tar...

Oppenheimer Maintains Outperform on Viridi...
08/07/2025 13:31:02

Oppenheimer analyst Leland Gershell maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price tar...

Needham Maintains Buy on Viridian Therapeu...
08/06/2025 18:07:34

Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $36...

Viridian Therapeutics Q2 EPS $(1.00) Beats...
08/06/2025 11:56:16

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of...

Viridian Therapeutics Signs $70M Upfront L...
07/30/2025 08:21:56

Kissei obtains an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan -Viridian to receive an upfro...

Needham Reiterates Buy on Viridian Therape...
05/20/2025 15:23:44

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $36 price target.

Viridian Therapeutics Announces Positive L...
05/20/2025 11:06:11

- 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week ...

What 5 Analyst Ratings Have To Say About V...
05/07/2025 22:00:53